Overview

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

Status:
Terminated

Trial end date:
2010-10-01

Target enrollment:

Participant gender:

Summary

The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial fibrillation (AF).

Phase:

Phase 3

Details

Lead Sponsor:

Sanofi

Treatments:

Biotin
Idrabiotaparinux
Idraparinux
SANORG 34006
Warfarin